The company said on Wednesday that it plans to present its data and the results of the REVIVE Phase 3 trials at IDWeek being held in San Francisco later this week.
READ: Pooled data from phase III trials confirms Motif Bio’s iclaprim drug is safer than gold standard
Motif Bio said 50% (602 out of 1198) of the REVIVE intent-to-treat (ITT) population had wound infections and that iclaprim was just as effective as vancomycin, based on an early clinical response of a subgroup of patients with wound infections.
The company also repeated that its drug was found not to negatively affect patients’ kidney function, a key issue for some people taking rival treatments. None of the patients taking iclaprim showed signs of kidney toxicity, compared to two patients in the vancomycin arm.
"Wound infections, including surgical site infections, can be difficult to treat and it was important to see that iclaprim was non-inferior to standard of care in treating these types of infections,” G. Ralph Corey, MD, Vice Chair for Education and Global Health and Gary Hock Professor at Duke University School of Medicine and a principal investigator in the REVIVE-2 trial, said in a statement.
“Iclaprim, if approved, could be a valuable treatment option for patients with wound infections … including patients with co-morbidities known to increase the risk of vancomycin-associated acute kidney injury, such as renal impairment, diabetes and obesity," he added.
Shares in Motif Bio were flat at 34.95p in early trade.